Navigation Links
IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial

sponse (CR), 2 partial responses (PR) and 6 stable disease (SD)) with duration of response ranging from 9.4 to 26.5 months. -- Assessment of pathological response in target sites in 4 patients (2 PR, 2 SD) showed: -- complete pathological regression after resection of target sites in 2 patients; and -- two patients were rendered free of disease after clinical stable disease and surgery of lung metastases. -- Progression free survival (PFS) was 4.8 months with a median follow-up of 12 months. -- Overall survival (OS) has not yet been reached as 21 patients are still alive. The survival rate at 9 months was 70%. -- Immune response: 26 out of 29 evaluated patients (90%) showed detectable TAA-specific CD8+ T cells with 18 patients (62%) showing boosted or appearance of anti-TAA specific CD8+ T cells. -- UVIDEM was well tolerated with toxicity limited to mild events with only one possibly related serious adverse event (SAE) reported (age related macular degeneration).

About UVIDEM

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma GMP manufacturing facilities in Irvine, California and in Paris, France. UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase II clinical trials was previously announced. Thirty-eight patients with malignant melanoma were included in the US Phase II study and 53 patients with resected stage II/III melanoma were included in the European randomized Phase II study.

About Melanoma

According to the American Cancer Society, in 2007 approximately 59,940
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... Watching action shows on TV may be bad for your ... snack food while watching action films and programs than something ... find that if you,re watching an action movie while snacking ... Tal, of the Cornell Food and Brand Lab, said in ... the program is, the more you will eat." The ...
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... York, NY (PRWEB) September 01, 2014 ... have been added to a federal litigation that continues ... South Carolina, Bernstein Liebhard LLP reports. , A ... claims now filed over the widely-used cholesterol medication by ... the drug. According to claims, Pfizer Inc. failed to ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... patients who do not respond to traditional therapy can ... transplant, according to an Indiana University School of Medicine ... England Journal of Medicine. , About 90 percent ... involves multiple courses of cisplatin, first used successfully in ...
... are urgently needed to reduce climate-altering carbon emissions that ... the World Health Organisation said Monday. ,Climate change ... in the region, according to WHO estimates. ,"So ... If the trend continues, it may have an impact on ...
... for tougher regulations on tobacco, as officials from 145 ... global efforts to stop smoking. ,The ... aims to find ways of harmonising national laws to ... from second-hand smoke. ,Hatai Chitanondh, the president ...
... who have difficulty recognizing familiar smells could be experiencing an ... Monday. ,Scientists already know that the first ... in an area of the brain that is home to ... Center in Chicago tested 589 people aged between 54 to ...
... Idaho in US had a miraculous escape while traveling by an ... the pilot last Wednesday from Twin Falls, Idaho, to Seattle when ... at a height of 20,000 ft. ,Rapid decompression occurred ... water bottle. Fogg's head and right arm were pulled outside the ...
... New York based Columbia University Medical Center has shown that ... form of alcohol use disorder at some point in ... the adults surveyed reported experiencing alcohol abuse, and 12.5 per ... an article published in the Archives of General Psychiatry, one ...
Cached Medicine News:Health News:Advanced therapy offers cure for relapsed cancer patient 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2Health News:Nurse Has Miraculous Escape as Window is Blown Off an Air Ambulance 2Health News:One-third of Adults Have Had Some Form of Alcohol Use Disorder During Their Lifetimes 2
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
... Nebulizer Small Volume Medication Mouthpiece 7FT O 2 ... ,An advanced jet design for fast treatment times ... with a tighter distribution (higher percentage of respirable ... ,Our AirLife™ brand Misty Max 10™ disposable nebulizers ...
Medicine Products: